AIM-HI Accelerator Fund Honors Anna D. Barker, Ph.D., with Inaugural Beacon Award for Women Leaders in Oncology
ROCKVILLE, MD – The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of [...]
Come With Us! 2022 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship
The AIM-HI Accelerator Fund (AIM-HI) brings together a worldwide community [...]
AIM-HI Accelerator Fund Announces Inaugural Beacon Award for Women Leaders in Oncology
ROCKVILLE, MD – AIM-HI Accelerator Fund, a non-for-profit that focuses [...]
2022 AIM-HI Women’s Venture Competition Announced 6 Semi-Finalists!
The AIM-HI Accelerator Fund (AIM-HI) just announced 6 Semi-Finalists for the [...]
First in the World! Arbele’s CDH17xCD3 Bispecific Antibody Received Clinical Trial Phase I Ethics Approval in Australia
On March 31, 2022, the clinical trial application of ARB202 [...]
2021 Highlights: Thank You for Supporting AIM-HI to Accelerate a Cure!
The year 2021 saw an unprecedented triumph of science as [...]
Applications Open for the 2022 AIM-HI Women’s Venture Competition!
We have great news to share! The 2022 AIM-HI Women’s Venture Competition is [...]
Celebrating Progress in Cancer Research and Entrepreneurship!
The AIM-HI Accelerator Fund is fiercely dedicated to accelerating the commercialization [...]
2021 Women’s Venture Competition Announced Semi-Finalists!
The AIM-HI Accelerator Fund just announced 10 semi-finalists for the [...]
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs
Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company [...]
